Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
|Articles|December 12, 2013
Phase II Study of an Omega-3 Fatty Acid in TNBC Survivors
Author(s)Neil M. Iyengar, MD
Neil M. Iyengar, MD, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.
Advertisement
Clinical Pearls
Neil M. Iyengar, MD, Fellow, Medical Oncology and Hematology, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.
- This phase II study looks to analyze whether DHA, an omega-3 fatty acid, will reduce circulating markers of inflammation in overweight/obese patients with a history of TNBC
- In another poster, it was hypothesized that targeting the inflammation-aromatase axis with an omega-3 fatty acid could decrease the risk for relapse or development of breast cancer
- This trial will look at breast tissue pre- and post-intervention to determine if there is a decreases in inflammatory markers after 3 months of treatment with the omega-3 fatty acid
<<<
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5